Aging is the single greatest challenge for biomedicine in the 21st century, with Geroscience emerging as an interdisciplinary field that seeks to define the genetic, molecular, and cellular mechanisms of aging that gives rise to numerous age-related diseases and disorders.

Over the years, researchers studying the basic science of ageing have sought to answer the question of how the ageing process affects the disease process, and while aging itself isn't a disease, the aging process represents a major risk factor for several chronic diseases and conditions, including frailty and lack of resilience.

It is an exciting time in the field of Geroscience, with recent advances allowing scientists and clinicians, for the first time, to consider interventions aimed at directly targeting the hallmarks of aging and prevent multiple diseases of aging simultaneously.  Our panel of thought leaders and innovators from across the Geroscience space will provide a broad update of research and innovation as well as considering: 

• What potential do existing drugs such as metformin and rapamycin have as anti-aging drugs?
• Should the destruction of ‘zombie’ cells a target of therapeutics?
• How does autophagy fit into the Geroscience space?
• As Geroscience is not classified as a disease, what regulatory challenges does this cause?
• What is the funding landscape like for clinical trials in this space?
• What role does AI play in Geroscience research?

Programme & Speakers

• 17.30 Delegate Registration, tea & coffee served
• 18.00 Welcome by OBN 
• 18.05 Keynote: Professor Paul Shiels, Professor of Epigenetics at the Institute of Cancer Sciences & Associate Professor at the Institute of Health & Wellbeing, University of Glasgow
• 18.25 Keynote: from Dr Marina Wiklander, Field Marketing Specialist, Research and Applied Lab Solutions Western Europe at Merck regarding the use of 3D cell technology to understand the pathology of dementia
• 18.55 Keynote: from Associate Prof. Lynne Cox, Department of Biochemistry at the University of Oxford who will share an update on their study of the molecular and cellular basis of aging
• 19.15 Company Presentation: Dr Raj Dattani, Director of Juvenescence, who aim to create a pipeline of approaches in every major area of aging research
• 19.30 Company Presentation: Dr Peter Hamley, CSO at Samsara Therapeutics, who aim to discover medicines that extend healthy lifespan, based on insights into the biochemical Hallmarks of Aging
• 19.45 Company presentation – Dr David Ives, CEO & Founder, Shift Bioscience, who are targeting the root causes of aging to extend healthy lifespan.
• 20.00 Q&A with audience and speakers
• 20.20 Networking over drinks and nibbles
• 21.00 Evening ends

One Nucleus members get one complimentary ticket per company.